series-b
Stage
2020
Founded
2
Investors
About
Granite Bio is a clinical-stage biotechnology company developing first-in-class therapeutic antibodies targeting the root causes of inflammatory, autoimmune, and fibrotic diseases by selectively depleting pathogenic cells.
Explore Granite Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.